IMPDH1 Gene Polymorphisms and AssociationWith Acute Rejection in Renal TransplantPatients
J Wang1, JW Yang2, A Zeevi3, SA Webber4, DM Girnita3, R Selby5, J Fu1, T Shah2, V Pravica1,2,IV Hutchinson1,2,5 and GJ Burckart1
Inosine 50-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway forpurine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA). Few variants of theIMPDH1 gene have been reported. The objective of this study was to identify and characterize IMPDH1 variants todetermine whether genetic variation contributes to differences in MPA response and toxicity in transplant patients.
Seventeen genetic variants were identified in the IMPDH1 gene with allele frequencies ranging from 0.2 to 42.7%.
In this study, 191 kidney transplant patients who received mycophenolate mofetil were genotyped for IMPDH1. Twosingle-nucleotide polymorphisms, rs2278293 and rs2278294, were significantly associated with the incidence of biopsy-proven acute rejection in the first year post-transplantation. Future studies of the multifactorial nature of acute rejectionmust consider IMPDH1 polymorphisms in MPA-treated patients.
Inosine 50-monophosphate dehydrogenase (IMPDH) (EC
18.104.22.168) is the rate-limiting enzyme in the pathway of
IMPDH210,11 and has substrate affinities and Ki values that
de novo biosynthesis of guanine by driving inosine monopho-
are virtually indistinguishable.12 In an IMPDH1-knockout
sphate (IMP) to xanthosine monophosphate with the
mouse model, IMPDH1 deletion inhibited T-cell activation
reduction of nicotinamide adenine dinucleotide (NAD). This
in response to anti-CD3 and anti-CD28 antibodies.13
enzyme is the target of mycophenolic acid (MPA), the active
Although MPA has been shown to inhibit the activities of
constituent of the prodrug mycophenolate mofetil (MMF),
both IMPDH1 and IMPDH2 isoforms in vitro, IMPDH2 is
which is widely used clinically to prevent allograft rejection
4.8 times more sensitive to MPA inhibition than IMPDH1.14
following solid organ transplantation.1 MPA is also used as
Several mutations in the IMPDH-binding site confer
an immunomodulator in immune-related diseases such as
variable degrees of resistance to MPA in the parasite
AIDS, lupus nephritis, myasthenia gravis, and immune
Tritrichomonas foetus, and varying drug-sensitive forms of
thrombocytopenic purpura.2–6 Unlike other cell types, which
this enzyme have been detected in Saccharomyces cerevisiae.
can use the salvage pathway for purine synthesis, lympho-
However, few studies have been reported on IMPDH gene
cytes are exclusively dependent upon the de novo pathway
variants in humans.15–17 Recent findings have shown that
catalyzed by IMPDH for the generation of guanosine
mutations in IMPDH1 cause autosomal-dominant retinitis
nucleotide.7,8 MPA uncompetitively, selectively, and reversi-
pigmentosa.18,19 No other changes in IMPDH1 that result in
bly inhibits this pathway and therefore inhibits cell
a change in the genotype–phenotype relationship have been
IMPDH has two isoforms named IMPDH1 and IMPDH2,
As maintenance of the balance between rejection and over-
and the genes that encode these proteins are located on two
immunosuppression is difficult, pharmacokinetic and pharmaco-
different chromosomes.9 IMPDH1 is located on chromosome
dynamic monitoring of MMF have been proposed to
7 region q32.1 and is constitutively expressed in all tissues.
optimize drug dosage and the administration schedule.20
1Department of Pharmacy, University of Southern California, Los Angeles, California, USA; 2The National Institute of Transplantation, Los Angeles, California, USA;3Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; 4Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania,USA; 5Department of Surgery, University of Southern California, Los Angeles, Califo rnia, USA. Correspondence: GJ Burckar t
Received 29 April 2007; accepte d 4 July 2007; advance online publication 12 Septe mber 2007.
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 83 NUMBER 5 | MAY 2008 711
Hale et al.21 previously reported that the area under curve
(AUC) of MPA is inversely associated with the likelihood of
To examine IMPDH1 genetic variation, 17 exons and the
allograft rejection after renal transplantation in patients
intron–exon boundary regions were initially sequenced from
receiving MMF. The relationship between MMF pharmaco-
30 genomic DNA samples from liver transplant patients.
kinetic parameters and the risk of adverse effects is not as well
Seventeen genetic variants were identified in the IMPDH1
defined. Considering the significant variability in the effects
gene. Eleven single-nucleotide polymorphisms (SNPs), in-
of a given concentration of MPA, the therapeutic range for
cluding four exonic variants and seven intronic SNPs with
the desired pharmacologic effect without adverse effects in
relatively high allele frequencies, were subjected to TaqMan
most patients is difficult to discern.22 Interindividual
SNP assay using an ABI 7900 Real-Time PCR System. The
variability in IMPDH activity has been observed in healthy
identified polymorphisms and their frequencies are listed in
volunteers as well as transplant patients.23,24 Pharmaco-
lists the demographic data for the 191 renal
dynamic monitoring of IMPDH activity has been proposed,
transplant patients who were divided into patients with and
and a significant relationship has been reported between
without an episode of biopsy-proven acute rejection in the
pretransplant IMPDH activity and clinical outcome after
first postoperative year. No significant demographic diffe-
renal transplantation.24 However, MPA is most frequently
rence was found between the group with rejection and
administered to transplant patients without monitoring MPA
without rejection with respect to age at transplantation,
plasma concentrations, IMPDH concentrations, or other
weight, height, gender, and race/ethnicity (P40.05). All of
the SNPs genotyped were in the Hardy–Weinberg equilibrium
The considerable variability in baseline IMPDH activity
and MPA response may logically be under the control of
Two novel non-synonymous variants, Asp301Asn and
genetic variation within the IMPDH genes or in gene
Gly519Arg, were identified in exons 10 and 15 of IMPDH1.
expression. Analysis of genetic variants could provide the
The effects of these polymorphisms were determined on
explanation for the variability of IMPDH activity and MMF
IMPDH production (see Supplementary Material, Table S4
response in transplant patients. Therefore, the objective of
and Figures S3 and S4), and neither was found to change
this study was to identify IMPDH1 genetic variants in renal
transplant patients and to retrospectively look for the
Biopsy-proven acute rejection occurred in 15% of patients
association of these polymorphisms with leukopenia or
in the first postoperative year, which approximates the rate of
biopsy-proven acute rejection in renal transplant patients
rejection observed currently in transplant centers in the
United States with a high percentage of high-risk patients.25
Table 1 Genetic variants of IMPDH1 in transplant patients detected by bidirectional DNA sequencing
IMPDH, inosine 50-monophosphate dehydrogenase; SNP, single-nucleotide polymorphism. aThe position is relative to ATG start site with the A as nucleotide +1 and based onmRNA sequence from GenBank accession number NM_000883. bThe frequencies were reported by GenBank. cAmino-acid (AA) change with its position shown in middle(NP_000874). Non-synonymous change is shown in bold. dTagging SNPs. eFrequencies based on sequencing in transplant patients.
VOLUME 83 NUMBER 5 | MAY 2008 | www.nature.com/cpt
Table 2 Demographic characteristics of the kidney transplant patients
MPA, mycophenolic acid. aData were represented as mean+SD.
Two SNPs, rs2278293 and rs2278294, were significantly
associated with the incidence of biopsy-proven acute
Numerous SNPs have now been associated with acute
rejection in the first year post-transplantation
rejection after renal transplantation. Most of these SNPs
Po0.05, w2). The prognostic value of each of these SNPs in
have been part of the transplant immune response and
predicting biopsy-proven rejection exceeded 50% for both
include cytokines, chemokines, adhesion molecules, and
the positive predictive value and the negative predictive value
growth factors. The pharmacogenetic factors affecting drug
. Both of these SNPs are intronic, and one is a
bioavailability, direct action, and disposition in organ
component of a haplotype block. The odds ratio by logistic
transplant patients have not been associated with acute
regression analysis was 0.34 for SNP rs2278293 (95%
rejection previously, with the exception of an ABCB1
confidence interval: 0.15–0.76; P ¼ 0.008) and 0.40 for
rs2278294 (95% confidence interval: 0.18–0.89; P ¼ 0.02).
Plasma concentrations of MPA are affected by a number of
Leukopenia occurred in approximately 32% of the
gene polymorphisms. Both the glucuronidating uridine 50-
patients receiving MPA in the first postoperative year
diphospho-glucuronosyltransferase (UGT) enzymes29–31 and
. In previous reports of leukopenia in MPA-treated
the drug transporter multidrug resistance-associated protein-2
transplant patients, leukopenia occurs in 25.9–39.3% of
(MRP2)32 polymorphisms may affect MPA plasma concen-
patients, depending on the criteria for classifying leuko-
trations. P-glycoprotein, MRP2, and the organic anion-
penia.26 Leukopenia was not associated with any of the
transporting polypeptide (OATP) transporters may play
IMPDH1 SNPs. We observed leukopenia in the one variant
a potential role in MPA disposition, so it is not surprising
IMPDH2 L263F patient in accordance with our previous
that considerable variability in MPA pharmacokinetics has
been observed in transplant patients.33shows that
Six tagging SNPs were selected to present the two
the critical step in exerting the effect of MPA is at IMPDH,
which is controlled by IMPDH1 and IMPDH2.
haplotypes, rs11770116–rs2288548 and rs2278294–rs2228075,
Our previous explorative study showed that IMPDH2 is
were also examined for their influence on leukopenia or acute
more conserved than its isoform IMPDH1. Although we
rejection within 1-year post-transplantation . No
identified a novel variant L263F that affects enzyme activity
haplotype association was found for leukopenia or acute
in IMPDH2,27 its rare frequency precludes it from having a
large effect in a small patient population. Another SNP,
The genotype distribution for all of the SNPs, with one
rs11706052, was not associated with the incidence of biopsy-
exception, was not statistically different between the Hispanic
proven rejection in this study. Owing to the low frequency of
and non-Hispanic patients (Table S2). The distribution was
the L263F variant, further studies in larger populations
significantly different for rs2288553, but this SNP was not
would be needed to define its impact on clinical outcome.
significantly associated with either acute rejection or
The IMPDH monomer contains eight-stranded a/b
barrels, which are the core domain of the IMPDH1 protein.
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 83 NUMBER 5 | MAY 2008
Table 3 The association of IMPDH1 and IMPDH2 SNPs with biopsy-proven rejection and leukopenia in kidney transplant patients
IMPDH, inosine 50-monophosphate dehydrogenase; SNP, single-nucleotide polymorphism. *Po0.05 for rejection by w2.
Table 4 Prognostic valuea of the IMPDH1 polymorphism for determining biopsy-proven rejection in kidney transplant patientstreated with MPA
CI, confidence interval; IMPDH, inosine 50-monophosphate dehydrogenase; MPA, mycophenolic acid. aMean value and 95% CI.
This area contains the entire machinery for enzyme catalytic
non-synonymous SNPs encode for G519R and D301N, which
activity, flanked by a subdomain composed of two regions
are both located at the flanking subdomain, and the in vitro
similar to the cystathionine b-synthase gene (CBS domain)
enzyme kinetic assay and filter-binding assay indicated that
(Figure S2). The subdomain of IMPDH can bind with
the functional consequences of these variants are minor.
nucleic acid with nanomolar affinity, but the function of this
A novel IMPDH1 gene mutation (Arg231Pro) is reported
DNA-binding property is yet to be determined. Our novel
to be associated with a severe form of autosomal-dominant
VOLUME 83 NUMBER 5 | MAY 2008 | www.nature.com/cpt
for approximately 2% of families with autosomal-dominantretinitis pigmentosa, and de novo IMPDH1 mutations are alsorare causes of isolated Leber congenital amaurosis.35 TwoIMPDH1 variants, Arg105Trp and Asn198Lys, were reportedin two patients with isolated Leber congenital amaurosis. TheAsp226Asn mutation is associated with a severe early-onsetform of retinal degeneration. Retinitis pigmentosa is a rare
disease, and we did not observe these variations in our
transplant patients. The only previous report relating to
transplant patients was that a 9-bp insertion within theIMPDH1 promoter region was found in a patient exhibiting
severe azathioprine resistance, possibly by reducing the
Hispanic renal transplant patients are considered to be
high-risk patients and have a higher rate of graft failure based
on United Network for Organ Sharing (UNOS) data than dothe Caucasian renal transplant patients.37 The rates of biopsy-
proven acute rejection have varied in high-risk renal
transplant populations given antibody-induction therapyfrom 15.6%38 to 26.4%39 but are as low as 5% at individualcenters.40 No evidence could be found in this study that the
Figure 1 LD patterns and haplotype blocks in kidney transplant patientswere defined according to the ‘‘solid spine of LD’’ setting in Haploview 3.2
inclusion of a significant number of Hispanic patients
software, which is under the analysis criteria solid spine of LD40.8. A
influenced our analysis of IMPDH1 polymorphisms and
standard color scheme is used to display LD pattern, with dark gray for very
biopsy-proven acute renal transplant rejection.
strong LD (log of likelihood odds ratio, logarithm of odds (LOD)X2, D0 ¼ 1),
The accurate assessment of those transplant patients who
white for no LD (LODo2, D0o1), and bright gray and shades of gray for
are at risk for the development of acute rejection will require
intermediate LD (LODX2, D0o1); increasing intensity of gray indicatesincreasing degrees of LD.
looking at a multiplicity of immune and pharmacologicfactors. In this population of renal transplant patients,IMPDH1 SNPs were prognostic of the development of
biopsy-proven acute rejection in the first postoperative year.
The mechanism of association between IMPDH1 polymorph-
isms and acute rejection is still to be determined. One
possible explanation is their linkage to other SNPs that may
control IMPDH1 mRNA expression, enzyme activity, and
ultimately lymphocyte proliferation. Future prospective
studies should examine the mechanism by which IMPDH1
polymorphisms might affect the immunologic response in
transplant patients receiving MPA. Both pharmacogenomicand immunogenetic factors will have to be considered in
developing treatment algorithms for transplant patients.41
This study supports the inclusion of IMPDH1 polymorph-
isms as one factor that must be tested in developing a panel
of gene polymorphisms used to assess the risk of acute
Figure 2 A graphic presentation of the involvement of multiple enzymes
rejection for transplant patients being treated with MPA.
and transporters affecting the action of MPA on lymphocyte proliferation.
Each of the polymorphisms designated by an asterisk may affect the plasma
concentrations of MPA either directly or through the enterohepatic
In the IMPDH-sequencing initial study, 30
recycling of mycophenolic acid glucuronide (MPAG), with the exception of
DNA samples of liver transplant patients at the University of
IMPDH. IMPDH is the target of MPA in de novo purine synthesis in
Southern California were screened to identify SNP candidates in
IMPDH1. In the following study, we genotyped 191 kidneytransplant patients from the National Institute of Transplantation(St Vincent’s Medical Center) in Los Angeles. All kidney transplant
retinitis pigmentosa. Five different IMPDH1 variants,
patients had been treated from the time of transplantation with
Thr116Met, Asp226Asn, Val268Ile, Gly324Asp, and His372-
tacrolimus, MMF, and prednisone-based immunosuppression, withthe exception of five patients who received cyclosporine in place of
Pro, have been identified in eight autosomal-dominant
tacrolimus. The therapeutic serum target level was 5–15 mg/ml for
retinitis pigmentosa families, but their functional significance
tacrolimus and 100–200 mg/ml for cyclosporine. MMF doses were
remains to be defined.18,19,34 Mutations in IMPDH1 account
adjusted based upon patient’s tolerance of the adverse effects of the
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 83 NUMBER 5 | MAY 2008
drug with respect to gastrointestinal side effects and development of
Allele and genotype frequencies were calculated
leukopenia. The following inclusion and exclusion criteria were used
for each locus and tested for Hardy–Weinberg equilibrium using
for the renal transplant study: (1) patients who underwent renal
transplantation from 2000 to 2005, with available DNA, and had
Determination of linkage disequilibrium (LD), tagging SNPs,
post-transplant survival more than 1 year with follow-up informa-
haplotype blocks, and frequencies were performed by using
tion available; (2) patients must have been on MMF for at least 1
Haploview version 3.2. Haplotype blocks were defined according
year; and (3) patients must not have been receiving antiviral
to the ‘‘solid spine of LD’’ setting in Haploview 3.2 software, which is
(valganciclovir, ganciclovir), anticancer, or other leukopenia-causing
under the analysis criteria solid spine of LD40.8.
medications at the time when leukopenia was recorded.
Each variant in IMPDH1 underwent univariate analysis for the
The protocols were approved by the institutional review boards
difference of allele distribution between patients with or without
of the University of Southern California and St Vincent’s Medical
leukopenia and between patients with or without rejection within
Center in Los Angeles. All patients or guardians provided informed
1-year post-transplantation by w2 test. Considering the low
written consent to undergo genotyping. Anticoagulated venous
frequency of the minor alleles, we combined the homozygous
blood was obtained from each patient, and DNA was extracted from
variant with the heterozygous patients. Therefore, the presence or
whole blood using a commercially available DNA extraction
absence of the variant alleles, instead of genotype, was compared in
procedure (Qiagen, Valencia, CA). Sequencing and genotyping were
this population. Multiple logistic regression analysis was performed
performed in patients who had been previously transplanted, and all
to examine the association between IMPDH1 variants and acute
patient information was collected retrospectively. Patients were
rejection in patients. For SNPs with P-value o0.05, clinical
managed according to the standard transplant center protocol,
prognostic values (sensitivities, specificities, negative and positive
which did not include monitoring of MPA plasma concentrations.
predictive values) were assessed for their association with acute
At most transplant centers, MPA doses are adjusted based upon
rejections occurring in the first postoperative year. All P-values
patient’s tolerance of the adverse effects of the drug with respect to
o0.05 were considered as significant. Statistical analysis was
gastrointestinal side effects and the development of leukopenia.
performed using the SPSS software program version 14.0 forWindows (SPSS, Chicago, IL).
SNP identification in the IMPDH1 gene was
The incidence of both leukopenia and rejection was treated as a
performed by PCR amplification followed by bidirectional direct
dichotomous trait. Patients with a white blood cell count 43,000/ml
DNA sequencing, as described previously.27 PCR was carried out in
were considered as not having leukopenia, and patients with a white
a total volume of 50 ml using 50 ng of genomic DNA, 5 pmol of each
blood cell p3,000/ml during MPA treatment were considered as
forward and reverse primer (Sigma, St Louis, MO), 0.2 mM dNTP
having leukopenia. Further subgroup analysis was carried out using
(Promega, Madison, WI), 1 Â PCR buffer, and 1.5 U of thermo-
the grades of leukopenia described by the Southwest Oncology
stable Taq DNA polymerase and Tgo DNA polymerase with
proofreading activity and high fidelity (Expand 20 kbPLUS PCRSystem; Roche Applied Science, Penzberg, Germany). The primers
SUPPLEMENTARY INFORMATION is linked to the online version of the
used are described in Table S1. The PCR process included initial
denaturation at 921C for 2 min and 10 cycles of denaturation at921C for 10 s, annealing at 571C for 30 s, and synthesis at 681C for
7 min followed by additional 25 cycles of denaturation at 921C for
This work was supported by 5P50 HL074732 from the National Heart Lung
10 s, annealing at 571C for 30 s, and synthesis at 681C for 7 min, with
and Blood Institute, National Institutes of Health.
the time extended by 10 s for each successive cycle. The finalelongation was carried out for 5 min at 721C. Amplified PCR
products were purified by using the Qiagen PCR purification kit
The authors declared no conflict of interest.
(Qiagen) and sequenced by conventional means using the BigDyeTerminator Cycle Sequencing Ready Reaction Kit on ABI 377 XL
ª 2007 American Society for Clinical Pharmacology and Therapeutics
Sequencer (Applied Biosystems, Foster City, CA). SNPs were
Allison, A.C. & Eugui, E.M. Mycophenolate mofetil and its mechanisms
identified by transferring the chromatograms to sequence assembly
of action. Immunopharmacology 47, 85–118 (2000).
software Sequencher 4.1.4 (Gene Codes, Ann Arbor, MI). Each base
Meriggioli, M.N., Rowin, J., Richman, J.G. & Leurgans, S. Mycophenolate
call was compared with the consensus sequence, and the SNPs were
mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot
confirmed by visual inspection of the chromatograms.
study. Ann. NY Acad. Sci. 998, 494–499 (2003).
For genotyping the SNPs identified, we genotyped 191 transplant
Provan, D., Moss, A.J., Newland, A.C. & Bussel, J.B. Efficacy of
patients by TaqMan assay using the ABI 7900 Real-Time PCR
mycophenolate mofetil as single-agent therapy for refractory
System (Applied Biosystems). Two oligonucleotide probes for each
immune thrombocytopenic purpura. Am. J. Hematol. 81, 19–25
SNP were synthesized by Applied Biosystems. DNA concentration
was measured photometrically and the DNA was diluted to a
Ginzler, E.M. et al. Mycophenolate mofetil or intravenouscyclophosphamide for lupus nephritis. N. Engl. J. Med. 353,
concentration of 2 ng/ml. Amplification was performed in a final
volume of 25 ml DNA solution at a concentration of 2 ng/ml,
Millan, O. et al. Pharmacokinetics and pharmacodynamics of low dose
100 pmol/ml of each probe, 2.5 ml of TaqMan Universal PCR Master
mycophenolate mofetil in HIV-infected patients treated with
Mix (Applied Biosystems), and distilled water. In every assay,
abacavir, efavirenz and nelfinavir. Clin. Pharmacokinet. 44, 525–538
controls for the wild type and mutations were included. Reaction
mixtures were loaded into 96-well plates and placed in an ABI Prism
Sankatsing, S.U. et al. Effect of mycophenolate mofetil on the
Sequence Detector 7900 (Applied Biosystems). The PCR conditions
pharmacokinetics of antiretroviral drugs and on intracellular
were as follows: initial denaturation at 951C for 10 min, followed by
nucleoside triphosphate pools. Clin. Pharmacokinet. 43, 823–832
40 cycles of denaturation (941C for 15 s), annealing, and extension
Fulton, B. & Markham, A. Mycophenolate mofetil. A review of its
pharmacodynamic and pharmacokinetic properties and clinical
A representative chromatogram of the (a) G519R and (b) D301N
efficacy in renal transplantation. Drugs 51, 278–298 (1996).
heterozygotes for the IMPDH1 gene is shown in Figure S1. The
Zaza, G. et al. Acute lymphoblastic leukemia with TEL-AML1 fusion
arrows indicate that the variant is C/T and A/G in the sense sequence
has lower expression of genes involved in purine metabolism and
(A, adenine; G, guanine; C, cytosine; and T, thymine).
lower de novo purine synthesis. Blood 104, 1435–1441 (2004).
VOLUME 83 NUMBER 5 | MAY 2008 | www.nature.com/cpt
Carr, S.F., Papp, E., Wu, J.C. & Natsumeda, Y. Characterization of
with low cyclosporine and steroid doses. Clin. Transplant. 12, 198–205
human type I and type II IMP dehydrogenases. J. Biol. Chem. 268,
Wang, J. et al. A novel variant L263F in human inosine 50-
Zimmermann, A.G., Wright, K.L., Ting, J.P. & Mitchell, B.S. Regulation
monophosphate dehydrogenase 2 is associated with diminished
of inosine-50-monophosphate dehydrogenase type II gene expression
enzyme activity. Pharmacogenet. Genomics 17, 283–290 (2007).
in human T cells. Role for a novel 50 palindromic octamer sequence.
Zheng, H.X. et al. The impact of pharmacogenomic factors on acute
J. Biol. Chem. 272, 22913–22923 (1997).
persistent rejection in adult lung transplant patients. Transplant.
Sanquer, S., Breil, M., Baron, C., Dhamane, D., Astier, A. & Lang, P.
Induction of inosine monophosphate dehydrogenase activity after
Bernard, O., Tojcic, J., Journault, K., Perusse, L. & Guillemette, C.
long-term treatment with mycophenolate mofetil. Clin. Pharmacol.
Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7
metabolizing enzymes on the formation of phenolic and acyl
Hager, P.W. et al. Recombinant human inosine monophosphate
glucuronides of mycophenolic acid. Drug Metab. Dispos. 34,
dehydrogenase type I and type II proteins. Purification and
characterization of inhibitor binding. Biochem. Pharmacol. 49,
Girard, H. et al. Identification of common polymorphisms in the
promoter of the UGT1A9 gene: evidence that UGT1A9 protein and
Gu, J.J. et al. Targeted disruption of the inosine 50-monophosphate
activity levels are strongly genetically controlled in the liver.
dehydrogenase type I gene in mice. Mol. Cell. Biol. 23, 6702–6712
Pharmacogenetics 14, 501–515 (2004).
Kuypers, D.R., Naesens, M., Vermeire, S. & Vanrenterghem, Y. The
Jain, J. et al. Regulation of inosine monophosphate dehydrogenase
impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9)
type I and type II isoforms in human lymphocytes. Biochem.
gene promoter region single-nucleotide polymorphisms T-275A and
C-2152T on early mycophenolic acid dose-interval exposure in de
Futer, O. et al. A mutational analysis of the active site of human type II
novo renal allograft recipients. Clin. Pharmacol. Ther. 78, 351–361
inosine 50-monophosphate dehydrogenase. Biochim. Biophys. Acta
Naesens, M., Kuypers, D.R., Verbeke, K. & Vanrenterghem, Y. Multidrug
Digits, J.A. & Hedstrom, L. Species-specific inhibition of inosine
resistance protein 2 genetic polymorphisms influence mycophenolic
50-monophosphate dehydrogenase by mycophenolic acid.
acid exposure in renal allograft recipients. Transplantation 82,
Biochemistry 38, 15388–15397 (1999).
McPhillips, C.C., Hyle, J.W. & Reines, D. Detection of the
Staatz, C.E. & Tett, S.E. Clinical pharmacokinetics and
mycophenolate-inhibited form of IMP dehydrogenase in vivo.
pharmacodynamics of mycophenolate in solid organ transplant
Proc. Natl. Acad. Sci. USA 101, 12171–12176 (2004).
recipients. Clin. Pharmacokinet. 46, 13–58 (2007).
Bowne, S.J. et al. Mutations in the inosine monophosphate
Kennan, A. et al. Identification of an IMPDH1 mutation in autosomal
dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal
dominant retinitis pigmentosa (RP10) revealed following comparative
dominant retinitis pigmentosa. Hum. Mol. Genet. 11, 559–568 (2002).
microarray analysis of transcripts derived from retinas of wild-type
Bowne, S.J. et al. Why do mutations in the ubiquitously expressed
and Rho(À/À) mice. Hum. Mol. Genet. 11, 547–557 (2002).
housekeeping gene IMPDH1 cause retina-specific photoreceptor
Bowne, S.J. et al. Spectrum and frequency of mutations in IMPDH1
degeneration? Invest. Ophthalmol. Vis. Sci. 47, 3754–3765 (2006).
associated with autosomal dominant retinitis pigmentosa and Leber
van Gelder, T. & Shaw, L.M. The rationale for and limitations of
congenital amaurosis. Invest. Ophthalmol. Vis. Sci. 47, 34–42 (2006).
therapeutic drug monitoring for mycophenolate mofetil in
Roberts, R.L., Gearry, R.B., Barclay, M.L. & Kennedy, M.A. IMPDH1
transplantation. Transplantation 80, S244–S253 (2005).
promoter mutations in a patient exhibiting azathioprine resistance.
Hale, M.D. et al. The pharmacokinetic–pharmacodynamic relationship
Pharmacogenomics J. doi:10.1038/sj.tpj.6500421 (2006).
for mycophenolate mofetil in renal transplantation. Clin. Pharmacol.
Press, R. et al. Race/ethnicity, poverty status, and renal transplant
outcomes. Transplantation 80, 917–924 (2005).
Kelly, P. & Kahan, B.D. Review: metabolism of immunosuppressant
Brennan, D.C. et al. Rabbit antithymocyte globulin versus basiliximab
drugs. Curr. Drug Metab. 3, 275–287 (2002).
in renal transplantation. N. Engl. J. Med. 355, 1967–1977 (2006).
Glander, P. et al. Non-radioactive determination of inosine
Meier-Kriesche, H.U. et al. The effect of daclizumab in a high-risk renal
50-monophosphate dehydro-genase (IMPDH) in peripheral
transplant population. Clin. Transplant. 14, 509–513 (2000).
mononuclear cells. Clin. Biochem. 34, 543–549 (2001).
Ciancio, G. et al. The use of daclizumab, tacrolimus and
Glander, P. et al. Pre-transplant inosine monophosphate
mycophenolate mofetil in African-American and Hispanic first renal
dehydrogenase activity is associated with clinical outcome after renal
transplant recipients. Am. J. Transplant. 3, 1010–1016 (2003).
transplantation. Am. J. Transplant. 4, 2045–2051 (2004).
Burckart, G.J., Hutchinson, I.V. & Zeevi, A. Pharmacogenomics and
Wilkinson, A. Progress in the clinical application of
lung transplantation: clinical implications. Pharmacogenomics J. 6,
immunosuppressive drugs in renal transplantation. Curr. Opin.
Nephrol. Hypertens. 10, 763–770 (2001).
Green, S. & Weiss, G.R. Southwest oncology group standard response
Moreso, F. et al. Incidence of leukopenia and cytomegalovirus disease
criteria, endpoint definitions and toxicity criteria. Invest. New Drugs
in kidney transplants treated with mycophenolate mofetil combined
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 83 NUMBER 5 | MAY 2008
Disentangling spillover e¤ects of antibiotic consumption:Published in Applied Economics (2013), 45, 8: 1041-1054,http://www.tandfonline.com/doi/abs/10.1080/00036846.2011.613790Literature on socioeconomic determinants of antibiotic consumption in thecommunity is limited to few countries using cross-sectional data. This paperanalyses regional variations in outpatient antibiotics in Italy using
Analysis of the Cost of Transgender Health Benefits The Cost of Transgender Health Benefits Mary Ann Horton, Ph.D. JPMorgan Chase Transgender at Work ABSTRACT This paper measures the frequency and cost of Transgender Health Benefits (THBs) for US residents. Itreports on a survey of surgeons who do Sex Reassignment Surgery (SRS) procedures, and reports thenumber of US residents